Company news
Sirnaomics Ltd. (HKEX:2257) news
Sirnaomics Ltd. news releases on 6ix. Latest, Sep 7, 2025: Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance…
Press releases & updates
Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines
September 6, 2025
Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development
October 4, 2024
Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology
September 19, 2024
Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine
July 30, 2024
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy
July 24, 2024
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
July 23, 2024
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics
July 8, 2024
Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients
June 28, 2024
Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy
June 13, 2024
Sirnaomics Announces 2023 Annual Results
March 28, 2024
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference
March 12, 2024
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024
February 5, 2024
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
January 24, 2024
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
December 5, 2023
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
December 1, 2023
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction
November 1, 2023
Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
August 29, 2023
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development
July 27, 2023
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
July 12, 2023
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company
July 5, 2023
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
June 19, 2023
Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty
June 5, 2023